| Filed On | Filing |
|---|---|
| 10 Nov 2026 | 10-Q |
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
Dosed first participant in Phase 1 clinical trial of HMB-003 for management of heavy menstrual bleeding, |
| 06 Nov 2026 | SCHEDULE 13G/A |
| 25 Sep 2026 |
Form 4: Walbert Keli, Director
Granted 36,000 Stock Option (Right to Buy) |
| 25 Sep 2026 |
Form 3: Walbert Keli, Director
No securities owned |
| 24 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 14 Aug 2026 | SCHEDULE 13G |
| 14 Aug 2026 | SCHEDULE 13G |
| 12 Aug 2026 | SCHEDULE 13G |
| 11 Aug 2026 | 10-Q |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
Multiple scientific data presentations, including five oral presentations across three programs, at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris, France |
| 07 Aug 2026 | SCHEDULE 13G |
| 06 Aug 2026 | SCHEDULE 13G |
| 05 Aug 2026 | SCHEDULE 13G |
| 17 Jun 2026 |
Form 4: Ra Capital MANAGEMENT, L.p., 10% owner and 3 others
Bought 6,146 shares ($153K) · Bought 61,523 shares ($1.54M) |
| 21 May 2026 |
Form 4: Ra Capital MANAGEMENT, L.p., 10% owner and 3 others
Bought 3,802 shares ($94.9K) · Bought 996 shares ($24.8K) |
| 21 May 2026 | 10-Q |
| 21 May 2026 |
8-K: Results of Operations and Financial Condition
Completed Initial Public Offering in May 2026, raising gross proceeds of $346.7 million and listing on Nasdaq |
| 14 May 2026 |
Form 4: Ra Capital MANAGEMENT, L.p., 10% owner and 3 others
Bought 6,387 shares ($159K) |
| 14 May 2026 |
Form 3: Ai Den-mab Llc, 10% owner and 4 others
Holds 4,876,344 shares of Common Stock |
Loading...